Safety Analysis of Baricitinib in Adult Patients With Severe Alopecia Areata From Two Randomized Clinical Trials Over a Median of 1.6 Years and Up to 3.6 Years of Exposure

September 2023 in “ Journal of the American Academy of Dermatology ”

Brett King, Justin Ko, Bianca Maria Piraccini, Yutaka Shimomura, Yves Dutron, Wen-Shuo Wu, Fan Emily Yang, Katrin Holzwarth, Chiara Chiasserini, Rodney Sinclair

Baricitinib alopecia areata randomized clinical trials

TLDR Baricitinib is a safe and effective treatment for severe alopecia areata.

The safety analysis of Baricitinib in adult patients with severe alopecia areata was conducted through 2 randomized clinical trials over a median of 1.6 years, with some participants having up to 3.6 years of exposure. The study involved multiple institutions, including Yale School of Medicine, Stanford University, and Eli Lilly and Company. The findings suggest that Baricitinib is a viable treatment option for severe alopecia areata, with a safety profile consistent with previous studies. The trials provide valuable long-term safety data, supporting the use of Baricitinib in managing this condition.

View this study on jaad.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 15 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 3 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 19 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 6 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

community Olumiant active ingredient Baricitinib

in Research/Science 1 upvotes 3 years ago

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Related Research

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.